Interferon Alfa-2a in the Treatment of Cutaneous T Cell Lymphoma
March 1989
in “
Journal of The American Academy of Dermatology
”
Studysummary This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer